EUCTR2021-000414-41-FR进行中（未招募）1 期
Multicentric Phase II-III study evaluating the tailored management of locally-advanced rectal carcinoma after a favorable response to Induction chemotherapy - GRECCAR14
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 430
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Written consent for study
- •2)Patients aged over 18 years old,
- •3)WHO performance status 0-1,
- •4)Histologically confirmed diagnosis of adenocarcinoma of the rectum,
- •5)Distal part of the tumor from 2 to 12 cm from the anal verge,
- •6)No unequivocal evidence of established metastatic disease,
- •7)MRI evaluation of the locally advanced tumor:
- •a)predictive CRM < 2mm
- •b)T3c-d (extending = 5mm beyond the muscularis propria) with EMVI (extra mural venous invasion)
- •c)T4a - b (except bone and sphincteric invasion),
- •8)General condition considered suitable for radical pelvic surgery and a systemic therapy with FOLFIRINOX,
- •9)Adequate hematologic, hepatic, renal and ionogram function assessed within 7 days prior to study treatment
- •a.Platelet count = 100,000/mm3; Hemoglobin (Hb) = 9 g/dL; Absolute neutrophil count (ANC) = 1,500/ mm3
- •b.Total bilirubin = 1.5 x ULN, Alkaline phosphatases = 3 x ULN and AST and ALT = 3 x ULN
- •c.Serum creatinine = 1.5 x ULN or calculated creatinine clearance = 50 ml/min according to MDRD,
- •d.Kalemia, Calcemia and Magnesemia within normal limits,
- •10)For women of reproductive potential, negative serum beta human chorionic gonadotropin (ß-HCG) pregnancy test obtained within 7 days before the start of study treatment. Women not of reproductive potential are female patients who are postmenopausal or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy),
- •11)For women of childbearing potential and men, agreement to use an adequate contraception for the duration of study participation and up to 6 months following completion of therapy for women and male patients. Females of childbearing potential who are sexually active with a non-sterilized male partner must use 2 methods of effective contraception. The investigator or a designated associate is requested to advise the patient on how to achieve an adequate birth control.
- •Adequate contraception is defined in the study as any medically recommended method (or combination of methods) as per standard of care,
- •12)No evidence of established or acute ischemic heart disease,
- •13)Willing to participate to the study, and able to give informed consent and to comply with the treatment and follow-up schedules,
- •14)Affiliation to the French Social Security System.
- •After neoadjuvant chemotherapy
- •-Patient with tumoral regression = 60% AND CRM = 1mm
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Non measurable rectal tumor or not assessed by MRI before inclusion
- •2)Ultra-low rectal tumor at diagnosis which imposes radiotherapy administration (inferior tumor pole less than 1 cm from the upper part of the levator ani)
- •3)Patient with a history of chemotherapy or pelvic radiotherapy
- •4)Contraindication to chemotherapy and/or radiotherapy
- •5)Complete or partial Dihydropyrimidine deshydrogenase (DPD) deficiency (uracilemia = 16 ng/mL)
- •6)Neuropathie sensitive périphérique = 2
- •7)ECG with a QT/QTc interval higher than 450 ms for men and higher than 470 ms for women
- •8)Active cardiac disease including any of the following:
- •a) Congestive heart failure = New York Heart Association (NYHA) class 2,
- •b) Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months),
- •c) Myocardial infarction less than 6 months before first dose of treatment,
- •d) Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).
- •9)Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to study inclusion, except for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non invasive tumor), Tis (carcinoma in situ) and T1 (lamina propria invasion)].
- •10)Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before start of treatment,
- •11)Any infection that could jeopardize treatment administration
- •12)Any other serious concomitant disease or disorder that may interfere with the patient's participation in the study and safety during the study (e.g., severe liver, heart, kidney, lung, metabolic, or psychiatric disorders).
- •13)History of inflammatory bowel disease
- •14)Patients with a history of pulmonary fibrosis or interstitial pneumonia
- •15)Patients using antivitamin K (Coumadin, etc...), it's possible to substitute the antivitamin K treatment with low molecular weight heparins (LMWHs) before starting chemotherapy.
- •16)Known hypersensitivity to any of the study drugs, study drug classes, or any constituent of the products.
- •17)Patient who received live attenuated vaccine within 10 days of inclusion
- •18)Pregnant or breastfeeding woman. If a patient is of childbearing age, she must have a negative pregnancy test (serum ß-hCG) documented 72 hours prior to inclusion.
- •19)Patients treated with systemic investigational drugs within the past 30 days
- •20)Patient under curatorship or guardianship or safeguard justice
- •21)Inability to submit to medical monitoring of the trial for geographical, social or psychological reasons.
研究者
相似试验
进行中（未招募）
1 期
Study evaluating the tailored management of locally-advanced rectal carcinomaRectum cancerMedDRA version: 20.0Level: LLTClassification code: 10007464Term: Carcinoma rectum Class: 10029104CTIS2024-511609-44-00Institut Regional Du Cancer De Montpellier430
进行中（未招募）
不适用
Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer - n.a.MedDRA version: 9.1Level: LLTClassification code 10033162Term: Ovarian epithelial cancer stage IIMedDRA version: 9.1Level: LLTClassification code 10033163Term: Ovarian epithelial cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10033164Term: Ovarian epithelial cancer stage IVMedDRA version: 9.1Level: LLTClassification code 10033161Term: Ovarian epithelial cancer stage IEpithelial Ovarian CancerEUCTR2006-004484-54-DEFresenius Biotech GmbH
进行中（未招募）
不适用
Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer - n.a.Epithelial Ovarian CancerEUCTR2006-004484-54-ATFresenius Biotech GmbH
已完成
不适用
A phase II study for the safety and efficacy of TAS-102 and Bevacizumab for patients with unresectable colorectal cancer considering Oxaliplatin to stop and go.unresectable colorectal cancerJPRN-UMIN000022535Gunma University45
招募中
3 期
Study of Out of Specification for TisagenlecleucelPediatric/young adult patients with r/r pALL and adult patients with r/r LBCL (including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma) for Part 1, and r/r ALL and r/r NHL for Part 2.JPRN-jRCT1080224903ovartis Pharma. K.K.200